Swissmedic

Swissmedic (Swiss Agency for Therapeutic Products) is Switzerland's national competent authority for medicines + medical devices + IVDs + transplant products + clinical trials. Swissmedic is an autonomous federal public-law institution under the supervision of the Federal Council + the Federal Department of Home Affairs (FDHA / EDI), headquartered in Bern, with approximately 500 staff. Swissmedic is funded primarily through fees + service charges + a federal contribution.

The Swissmedic ecosystem includes:

• Swissmedic HQ Bern — medicines authorisation, GMP / GDP inspectorate, device + IVD oversight, pharmacovigilance, market surveillance, enforcement.
• Swissmedic Cantonal Inspectorates — Swissmedic delegates GMP / GDP / GCP inspections to four Cantonal Inspectorates (Regio Inspektorate Nordwestschweiz, Heilmittelinspektorat der Nordostkantone, Regionales Heilmittelinspektorat der Ostschweiz, Regionales Heilmittelinspektorat der Zentralschweiz) covering ~26 Swiss cantons.
• Federal Office of Public Health (FOPH / BAG / OFSP) — public-health policy + clinical-trial coordination with Swissmedic.
• Swiss Federal Institute of Intellectual Property (IGE/IPI) — patent + supplementary protection certificates.
• Federal Office for Customs + Border Security (BAZG) — import / export enforcement.
• Swiss Notified Bodies — historically SQS + TÜV SÜD Switzerland; post-MRA-freeze with EU, Swiss NBs operate within Swiss + EU frameworks with separate designation paths.
• Cantonal Pharmacists + Public Health Authorities — pharmacy + retail oversight, hospital pharmacovigilance.

Legal foundations are the Therapeutic Products Act (HMG/LPTh, SR 812.21 — the umbrella law), the Medicinal Products Ordinance (VAM, SR 812.212.21), the Medical Devices Ordinance (MepV/ODim, SR 812.213), the In-Vitro Diagnostics Ordinance (IvDV/ODiv, SR 812.219), the Clinical Trials Ordinance (KlinV, SR 810.305), the Human Research Act (HFG, SR 810.30) + a body of Swissmedic Guidance + Administrative Decisions.

Swissmedic is a PIC/S founding member (1995), an ICH Standing Member (one of six founding members in 1990), an MHRA International Recognition Procedure Reference Regulator (since Jan 2024), an Access Consortium / ACSS member alongside TGA + Health Canada + Singapore HSA, an MDSAP Recognising Authority + an ICMRA / IMDRF active participant. Swissmedic is widely regarded as one of the most internationally integrated regulators globally per capita.

Understanding Switzerland's unique position outside the EU + EEA is essential. The Swiss-EU Mutual Recognition Agreement (MRA, in force 1 June 2002) covers conformity assessment for many product sectors including pharmaceuticals (medicines GMP) + medical devices. The MRA's medicines chapter remains operative; the device chapter has NOT been updated since EU MDR (entered application 26 May 2021) + IVDR (entered application 26 May 2022). The EU has formally treated Switzerland as a third country for devices since those dates — meaning Swiss-manufactured devices need an EU Authorised Representative for the EU market + EU-manufactured devices need a Swiss Authorised Representative (CH-REP) for the Swiss market.

• EU MRA — Medicines GMP chapter: in force, fully operative; PIC/S Membership of both Swissmedic + most EU national authorities reinforces reliance. EU GMP certificates accepted for Swiss medicines + vice versa.
• EU MRA — Devices chapter: NOT updated since EU MDR / IVDR; Switzerland treated as a third country since 26 May 2021 (MDR) + 26 May 2022 (IVDR). Bilateral framework agreement negotiations on EU-Swiss relations more broadly are ongoing.
• Swiss MDR (MepV) + IvDV — Switzerland enacted national device + IVD ordinances that substantively mirror EU MDR / IVDR effective 26 May 2021 / 26 May 2022; Swiss MepV recognises CE-marking certificates from EU Notified Bodies as evidence for Swiss-market placement (one-way recognition).
• Swiss Authorised Representative (CH-REP) — foreign device manufacturers must designate a CH-REP within Switzerland; CH-REP details required on labelling + IFU per class + timeline rules.
• CH-IB — Swissmedic-designated Notified Bodies for Swiss-market device certification (limited Swiss-NB ecosystem; most certification flows via EU NBs accepted under MepV).
• Importer / Distributor obligations — Swiss importers + distributors of medical devices have obligations under MepV substantively aligned with EU MDR Articles 13-14.
• Bilateral framework — Switzerland + EU ongoing negotiations on a broader bilateral framework that may or may not eventually restore the device MRA chapter; current Swiss position is that national bridging measures + MepV are sustainable indefinitely.
• Practical impact — for most medicines, Swissmedic-EMA continues to function smoothly via MRA + PIC/S + ICH; for devices, foreign manufacturers + Swiss companies must operate with explicit Swiss + EU dual frameworks + CH-REP / EU-REP designations.

• MepV (Medical Devices Ordinance) — substantively mirrors EU MDR; Class I / IIa / IIb / III + AIMD classification rules.
• IvDV (In-Vitro Diagnostics Ordinance) — substantively mirrors EU IVDR; Class A / B / C / D classification.
• Swiss Authorised Representative (CH-REP) — foreign manufacturers must designate a CH-REP within Switzerland; CH-REP is the legal point of contact for Swissmedic + responsible for regulatory compliance.
• CHRN (Swiss Single Registration Number) — Swissmedic-issued unique registration number for foreign manufacturers + Swiss manufacturers + CH-REPs + importers; required for market placement.
• Notified Body — Swiss CH-IB Notified Bodies + EU Notified Bodies whose certificates are recognised under MepV; certification path depends on device class + manufacturer choice.
• MDSAP — Swissmedic is an MDSAP Recognising Authority; MDSAP audit reports accepted as part of QMS evidence for Swissmedic inspections.
• Conformity assessment — Class I self-certification (with limited exceptions like sterile / measuring / reusable surgical Class Ir / Im / Is); Class IIa / IIb / III + AIMD require Notified Body involvement.
• Clinical evaluation — per MepV Article 47-55 + Annex XIV substantively aligned with EU MDR; PMS + PMCF requirements + PSUR (or PSAR) for higher-class devices.
• EUDAMED participation — Switzerland is NOT a participant in EUDAMED (the EU device database); Swissmedic operates parallel registration via CHRN + Swiss device database.
• UDI — Swiss UDI requirements substantively aligned with EU MDR / IVDR UDI; GS1 + HIBCC + ICCBBA recognised as issuing entities.
• Vigilance — Swissmedic Vigilance reporting per MepV Article 66-69 + IvDV Article 59-62; aligned with EU MDR / IVDR vigilance timelines + content.
• Importer + Distributor obligations — MepV Articles 53-54 substantively aligned with EU MDR Articles 13-14.

• Swissmedic + Cantonal Inspectorates — Swissmedic delegates GMP / GDP / GCP inspections to four Cantonal Regio Inspektorate covering all Swiss cantons.
• PIC/S founding member since 1995 — Swissmedic GMP inspections + reports accepted by all PIC/S members under PIC/S MoU; comprehensive worldwide reliance.
• EU MRA (medicines) — operative; EU GMP certificates accepted for Swiss medicines + vice versa.
• ICH Standing Member since 1990 — Swissmedic is one of the six founding ICH Members; Swiss medicines ordinances adopt ICH guidelines verbatim.
• Data integrity — Swissmedic Data Integrity Guidance substantively aligned with PIC/S PI 041 + MHRA + WHO + FDA; ALCOA+ + audit-trail + computerised-systems expectations.
• Overseas inspections — Swissmedic conducts overseas inspections of foreign sites supplying Switzerland; risk-based programme prioritising new MA applications + biologics + sterile products + APIs.
• Foreign GMP recognition — Swissmedic accepts PIC/S-member GMP certificates + EU MRA evidence + on a case-by-case basis bilateral arrangements (e.g. FDA via informal information-sharing).
• Inspection findings + remediation — Swissmedic Inspection Reports + Warning Letters + manufacturing-licence suspension; published market actions on Swissmedic portal.
• Swissmedic Quality Defects + Recalls — Swissmedic-coordinated recall execution with cantonal authorities + Swiss healthcare-system stakeholders.

• ElViS (Electronic Vigilance System) — Swissmedic's electronic ICSR + vigilance reporting platform; E2B(R3)-compliant; integrated with WHO VigiBase via UMC Uppsala + EudraVigilance gateway.
• ICSR reporting — Serious unexpected ADRs within 15 calendar days; non-serious in periodic reports + PSURs per ICH E2D + Swissmedic Vigilance Guidance.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle; Swissmedic reviews + aligns with EMA PRAC where applicable.
• Risk Management Plan (RMP) — required for new active substances + biosimilars + significant new indications; per ICH E2E + Swissmedic RMP guidance substantively aligned with EU RMP.
• Swiss Pharmacovigilance Officer — local QPPV-equivalent role required for Swiss MAH; substantively aligned with EU QPPV role.
• Vigilance reporting via cantonal pharmacists + hospital pharmacovigilance — Swiss healthcare-system reporting routes complement MAH reporting.
• Medical device vigilance — per MepV Article 66-69 + IvDV Article 59-62; FSCAs + serious-incident reports to Swissmedic.
• Recall — Swissmedic-coordinated recall framework with Cantonal Inspectorates + Swiss distribution + hospital systems.
• Drug Shortages — Swissmedic Drug Shortage Reporting System; MAHs required to report shortages of essential medicines.
• Black Triangle equivalent — Swissmedic uses additional monitoring symbols + warnings for new active substances + conditional authorisations.

• ICH Standing Member since 1990 — one of the six ICH founding members; Swissmedic actively contributes to ICH Working Groups.
• PIC/S founding member since 1995 — full reliance under PIC/S MoU with all PIC/S members.
• EU MRA (medicines) — operative since 1 June 2002; comprehensive EU-Swiss medicines GMP recognition.
• MHRA International Recognition Procedure — Swissmedic is one of seven IRP Reference Regulators since Jan 2024; Swissmedic approval bridges to UK MA via IRP.
• Access Consortium / ACSS — member alongside TGA + Health Canada + Singapore HSA + MHRA; multilateral medicines + devices regulatory cooperation.
• MDSAP — Recognising Authority; MDSAP audit reports accepted for Swiss device QMS evidence.
• ICMRA — active member contributing on pandemic preparedness, supply chain, real-world evidence, regulatory innovation.
• IMDRF — active participant on UDI, SaMD, AI / ML work products.
• Bilateral MoUs — Swissmedic has bilateral arrangements with FDA, Health Canada, TGA, MHRA, PMDA, MFDS, Singapore HSA + many others.
• WHO collaboration — Swissmedic is a WHO Listed Authority; supports WHO PQ + Collaborative Registration Procedure for LMIC NRAs.
• Reference Regulator for many emerging markets — Swissmedic approval is a recognised + relied-upon Stringent Regulatory Authority equivalent for many emerging-market reliance pathways.

• Swiss MAH / Swiss Authorised Representative not properly designated — application or device market-placement rejected at intake.
• CHRN (Swiss Single Registration Number) not obtained or out of date — device market-placement blocked.
• CH-REP details missing or non-compliant on labelling + IFU — Swissmedic market-placement enforcement action.
• Confusion about EU MDR / IVDR vs Swiss MepV / IvDV — companies assuming EU CE marking is sufficient for Swiss market without designating CH-REP + CHRN.
• Three-language labelling gap — Swiss labelling typically requires German + French + Italian (the three national languages); Swissmedic enforcement on incomplete language coverage.
• Reliance Procedure (Article 13 HMG) — applicants submitting partial foreign assessment without the full Day-0 to Day-X assessment report + Swiss-specific data.
• ElViS pharmacovigilance reporting timelines missed — Swiss QPPV / pharmacovigilance enforcement.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data.
• Sterile / aseptic process gaps — Swiss inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• Cantonal inspectorate coordination gap — manufacturers + MAHs not properly engaging with the relevant Cantonal Regio Inspektorat for site inspections.
• MDSAP audit-report packaging gap — Swissmedic accepts MDSAP but requires the full audit report + non-conformity closures, not just a certificate summary.
• Swiss UDI not aligned with EU UDI database — companies maintaining separate datasets that drift apart over time.
• Importer + Distributor obligations gaps — MepV Articles 53-54 obligations frequently not fully implemented by Swiss-resident importers + distributors.
• PSUR not aligned with International Birth Date — Swiss PSUR cycle out of sync with EMA PSUR / FDA PADER submissions.
• Medical device clinical evaluation gap — Swiss MepV substantively aligned with EU MDR clinical-evaluation expectations; legacy products with insufficient clinical evidence flagged at recertification.

V5 Ultimate provides the operational infrastructure Swiss + foreign-supplier sites need for HMG / VAM / MepV / IvDV compliance + Swissmedic readiness.

• Swissmedic GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + Swissmedic Data Integrity Guidance alignment.
• Swiss MAH + Swiss Authorised Representative (CH-REP) workflow — MAH-of-record + CH-REP designation, CHRN issuance + lifecycle tracking, EU-MA bridge tracking for Reliance Procedure submissions.
• Three-language labelling + IFU — German + French + Italian artwork control with two-person review + e-signature; Swissmedic-required elements + Swiss healthcare-system specifics.
• Reliance Procedure (Article 13 HMG) packaging — foreign-regulator assessment report packaging (FDA / EMA / Health Canada / TGA / PMDA / MHRA / Singapore HSA), Swiss-specific data overlay, Day-0 to Day-X assessment-report flow.
• MHRA IRP reverse-direction bridging — for Swissmedic approvals being bridged to UK MA via MHRA IRP Route A / B; Swissmedic assessment-report packaging for MHRA submission.
• MepV / IvDV device licensing workflow — Class I-III + AIMD + Class A-D IVD classification, CH-REP + CHRN + EUDAMED-equivalent Swiss registration, EU Notified Body + Swiss CH-IB certificate management.
• MDSAP audit-report packaging — for Swissmedic device QMS evidence; non-conformity closure tracking + MDSAP audit-cycle alignment.
• Swiss UDI — UDI-DI assignment + UDI-PI lifecycle + Swiss device database submission + EU UDI synchronisation for dual-market companies.
• ElViS pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Swiss QPPV workflow + cantonal pharmacist coordination.
• Medical device vigilance — FSCA + serious-incident reporting per MepV Article 66-69 + IvDV Article 59-62; UDI-linked surveillance + EU MDR / IVDR vigilance synchronisation.
• Cantonal Inspectorate coordination — site mapping to the relevant Regio Inspektorat (Nordwestschweiz / Nordostkantone / Ostschweiz / Zentralschweiz), inspection preparation, deficiency-tracking + CAPA + remediation timelines.
• Swiss-EU dual-market workflow — for companies operating in both Switzerland + EU, V5 surfaces dual-MA + dual-CHRN + EU/CH-REP + dual-labelling + dual-vigilance reporting in a single tenant.